Viridian TherapeuticsVRDN
VRDN
About: Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
Employees: 143
0
Funds holding %
of 7,431 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
25% more funds holding in top 10
Funds holding in top 10: 8 [Q1] → 10 (+2) [Q2]
7% more capital invested
Capital invested by funds: $1.23B [Q1] → $1.32B (+$88.6M) [Q2]
3.62% more ownership
Funds ownership: 112.12% [Q1] → 115.73% (+3.62%) [Q2]
5% less repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 64
4% less funds holding
Funds holding: 176 [Q1] → 169 (-7) [Q2]
21% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 28
34% less call options, than puts
Call options by funds: $1.81M | Put options by funds: $2.72M
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$26
39%
upside
Avg. target
$33
74%
upside
High target
$41
119%
upside
5 analyst ratings
4 positive
80%
1 neutral
20%
0 negative
0%
Goldman Sachs Richard Law | 60%upside $30 | Buy Maintained | 7 Aug 2025 |
RBC Capital Lisa Walter | 119%upside $41 | Outperform Maintained | 7 Aug 2025 |
Wells Fargo Derek Archila | 39%upside $26 | Equal-Weight Maintained | 7 Aug 2025 |
Oppenheimer Leland Gershell | 71%upside $32 | Outperform Maintained | 7 Aug 2025 |
Needham Serge Belanger | 82%upside $34 | Buy Maintained | 6 Aug 2025 |
Financial journalist opinion
Based on 6 articles about VRDN published over the past 30 days
Positive
Benzinga
2 weeks ago
These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results
Viridian Therapeutics, Inc. VRDN reported upbeat results for the second quarter on Wednesday.
Neutral
The Motley Fool
2 weeks ago
Viridian (VRDN) Q2 Net Loss Widens 55%
Viridian (VRDN) Q2 Net Loss Widens 55%
Neutral
Zacks Investment Research
2 weeks ago
Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates
Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1 per share in line with the Zacks Consensus Estimate. This compares to a loss of $1.02 per share a year ago.
Neutral
Business Wire
2 weeks ago
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the second quarter ended June 30, 2025. “Veligrotug's recent Breakthrough Therapy Designation as well as the continued and consistent performance of veligrotug across all of the endpoints and timepoints in our.
Neutral
Business Wire
3 weeks ago
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company's Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an aggregate of 181,450 shares of the company's common stock to 4 new employees (th.
Neutral
Business Wire
3 weeks ago
Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that it has entered into an exclusive collaboration and license agreement with Kissei Pharmaceutical Co., Ltd. (“Kissei”) to develop and commercialize veligrotug and VRDN-003 in Japan. Both molecules are anti-insulin-like growth factor-1 receptor (IGF-1R) a.
Neutral
Business Wire
1 month ago
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company's Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an aggregate of 175,000 shares of the company's common stock to one new employee (t.
Positive
Seeking Alpha
2 months ago
Viridian Therapeutics: The Song Remains The Same
Viridian Therapeutics is targeting thyroid eye disease with late-stage assets, and shares have dropped significantly over the past six months, despite no major negative news. Analyst sentiment remains bullish, with multiple Buy ratings and price targets far above current levels. The company has a couple of milestones upcoming in 2025 and more pivotal once scheduled in 2026 including a likely FDA approval.
Neutral
Business Wire
2 months ago
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company's Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an aggregate of 23,400 shares of the company's common stock to one new employee (th.
Neutral
Business Wire
2 months ago
Viridian Therapeutics to Participate in Upcoming June Investor Conferences
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that members of its management team will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference (New York, NY): Presentation on Wednesday, June 4, at 7:35am ET Goldman Sachs 46th Annual Global Healthcare Conferenc.
Charts implemented using Lightweight Charts™